Detalhe da pesquisa
1.
The INFINITY study protocol: a retrospective cohort study on decision making and clinical impact of biomarker-driven precision oncology in routine clinical practice.
BMC Cancer
; 23(1): 543, 2023 Jun 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37312086
2.
Pomalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of the non-interventional study POSEIDON and comparison with the pivotal phase 3 clinical trials.
Eur J Haematol
; 108(2): 133-144, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34714555
3.
Patient, nurse, and physician preferences: final results of the CONVENIENCE study evaluating pegfilgrastim prophylaxis via pre-filled syringe or on-body injector in cancer patients.
Support Care Cancer
; 29(11): 6633-6643, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-33956213
4.
Prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia with lipegfilgrastim in patients with non-Hodgkin lymphoma (NADIR study).
Eur J Haematol
; 102(2): 174-181, 2019 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-30347466
5.
Impact of S100A8/A9 expression on prostate cancer progression in vitro and in vivo.
J Cell Physiol
; 229(5): 661-71, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24122301
6.
Hypoxia and HIF-1 increase S100A8 and S100A9 expression in prostate cancer.
Int J Cancer
; 131(12): 2785-94, 2012 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22505354
7.
Prophylaxis of chemotherapy-induced neutropenia with lipegfilgrastim in patients with lung cancer: final results from the non-interventional study NADIR.
Curr Med Res Opin
; 38(12): 2191-2199, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36047998
8.
Prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia with lipegfilgrastim in 2489 cancer patients: final results from the non-interventional study NADIR.
Curr Med Res Opin
; 35(7): 1127-1138, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30557099
9.
Final Effectiveness and Safety Results of NABUCCO: Real-World Data From a Noninterventional, Prospective, Multicenter Study in 697 Patients With Metastatic Breast Cancer Treated With nab-Paclitaxel.
Clin Breast Cancer
; 18(6): e1323-e1337, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30100104
10.
Janus kinase 2--a novel negative regulator of estrogen receptor α function.
Cell Signal
; 24(1): 151-61, 2012 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-21907792
11.
Prostaglandin E2 stimulates S100A8 expression by activating protein kinase A and CCAAT/enhancer-binding-protein-beta in prostate cancer cells.
Int J Biochem Cell Biol
; 44(11): 1919-28, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-22728165
12.
ß-Catenin Is a Positive Regulator of Estrogen Receptor-α Function in Breast Cancer Cells.
Cancers (Basel)
; 3(3): 2990-3001, 2011 Jul 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-24212942
13.
Involvement of drug transporters in the synergistic action of FOLFOX combination chemotherapy.
Biochem Pharmacol
; 78(11): 1366-73, 2009 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19622348